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SUMMARY
Influenza immunization rates among young asthmatics remain unsatisfactory due to persistent
concern about the impact of influenza and the benefits of the vaccine. We assessed the
effectiveness of the conventional inactivated trivalent sub-unit influenza vaccine in reducing
acute respiratory disease in asthmatic children. We conducted a two-season retrospective cohort
study covering the 1995–6 and 1996–7 influenza outbreaks in 22 computerized primary care
practices in the Netherlands. In total, 349 patients aged between 0 and 12 years meeting
clinical asthma-criteria were included; 14 children were lost to follow-up in the second season.
The occurrence of physician-diagnosed acute respiratory disease episodes including influenza-
like illness, pneumonia, bronchitis, bronchiolitis, asthma exacerbation and acute otitis media in
vaccinated and unvaccinated children were compared after adjustments for age, prior health
care and medication use. The occurrence of acute respiratory disease in unvaccinated children
was 28% and 24% in the 1995–6 and 1996–7 season, respectively, and was highest in children
under 6 years of age (43%). The overall pooled clinical vaccine effectiveness was 27% (95%
confidence interval fi7 to 51%, Pfl 0–11) after adjustments. A statistically higher vaccine
protectiveness of 55% (95% CI 20–75%, Pfl 0–01) was observed among asthmatics under 6
years of age compared with fi5% in older children (95% CI fi81 to 39%). The occurrence of
acute respiratory disease among asthmatic children during influenza epidemics is very high,
notably in the youngest. Influenza vaccination may reduce morbidity in asthmatic infants and
pre-school children. However, larger, preferably experimental, studies are needed to establish
the benefits of vaccination, notably in older asthmatic children.
INTRODUCTION
Asthma is one of the commonest chronic conditions in
childhood with a prevalence of approximately 7% [1].
An important causal agent in asthma exacerbation is
influenza, especially during epidemics [2, 3]. Influenza
has a major impact on children’s well-being and
need for medical treatment [4–6] and predisposes to
complications such as pneumonia [7] and acute otitis
media [7–10]. Annual influenza vaccination is there-
* Author for correspondence.
fore recommended worldwide for this population at
risk [11].
Despite this recommendation, the low costs of the
vaccine and the absence of systemic side-effects [2, 12]
immunization rates remain low [11]. This seems
mainly attributable to both the physician’s and
patient’s doubt about the clinical protectiveness of the
vaccine [13, 14]. So far, only indirect protectiveness
against serologically proven influenza infection has
been demonstrated in children (42–95% relative risk
reduction) [8, 15]. Furthermore, few studies have
provided evidence of a reduction in acute otitis media
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rates and febrile illness episodes following influenza
vaccination [8–10, 15]. The vaccine’s clinical protec-
tiveness against acute respiratory disease (including
influenza-like illness, pneumonia, bronchitis, bron-
chiolitis, asthma exacerbation and acute otitis media)
in asthmatic children has not been demonstrated
[2, 16, 17]. We therefore evaluated, in a primary care-
based, two-season study, whether influenza vacci-
nation is effective in reducing the occurrence of acute
respiratory disease in asthmatic children. In addition,
we assessed whether the impact of influenza-associ-
ated morbidity and the effectiveness of influenza
vaccination are different in infants and pre-school
children as compared with schoolchildren.
METHODS
Design
Our study was designed as a retrospective cohort
study. We defined a cohort of young asthmatics
originating from a primary care database in 1995.
This cohort was followed up during two consecutive
years and influenza seasons (1995–6 and 1996–7).
Setting
Twenty-two general practitioners in five primary care
centres participated in the study. The practices covered
a representative sample of approximately 40000 pa-
tients. Practices are members of the Utrecht University
General Practice Network [18] and are situated in
urban as well as rural areas in the central part of
the Netherlands. All physicians used computerized
medical records to register patient contacts. Diagnoses
were coded according to the International Classifica-
tion of Primary Care (ICHPPC-2) and therapeutic
agents according to the Anatomical Therapeutic
Classification (ATC) [19–21]. All physicians regularly
received extensive training in uniform registration of
respiratory tract diseases. Anonymous use of patient
information for scientific research derived from the
database has been approved by the medical ethical
committee of the University Medical Center Utrecht.
Subjects
First, a pre-selection of potential study subjects was
performed using a ‘computerized influenza prevention
module’ [22]. This module identified patients in high-
risk categories for influenza infection on the basis of
disease tags, ICPC- and ATC-codes. Potential study
subjects were selected by their physicians on the basis
of asthma criteria defined in the guidelines of the
Dutch College of General Practitioners [23].
These criteria stated that in a patient under 6 years
of age (probable) asthma was a clinical diagnosis
based on symptoms and signs only. Required criteria
were: recurrent episodes of coughing and}or con-
gestion (" 5 times a year, " 10 days an episode) or
wheezing associated with a viral infection and one of
the following:
E improvement of complaints following a broncho-
dilator or
E indications of allergic stimuli causing airway
symptoms or
E constitutional eczema or
E increase of wheezing and}or dyspnoea with age or
E asthma, hay-fever or eczema in a first-degree
sibling.
In children aged 6–12 years, the same criteria were
required in addition to pulmonary function measure-
ments. Asthma was confirmed when forced expiratory
volumeorpeakflowmeasurementindicatedareversible
bronchial obstruction and}or when day–night
variability (amplitude}mean " 31%) was present.
We admitted 370 young asthmatics aged 0–12 years
meeting the above-mentioned criteria in November
1995. To ensure current asthma activity, we excluded
21 children that did not contact their physician in the
year preceding the inclusion date. Fourteen subjects
were lost to follow-up in the second season and
consequently excluded in the 1996–7 season
Intervention
Influenza vaccination was offered to patients in
accordance with guidelines of the Dutch College of
General Practitioners [24]. Annually, the parents of
indicated patients received a personal postal invi-
tation. Mass vaccination of children and parents who
responded took place each year in the first 2 weeks of
November. Children under 6 years of age received
another dose 4 weeks after the first, if they had not
received a vaccine in prior years. Each year the
trivalent sub-unit vaccine was composed of strains
recommended by the World Health Organization.
Influenza seasons
Influenza monitoring was performed by the Dutch
National Influenza Centre in collaboration with the
Dutch Sentinel Practice Network [25, 26]. We defined
influenza seasons as the period in which the incidence
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of influenza-like-illness reported by the sentinel prac-
tices was above 4 per 10000 inhabitants per week. The
first season started in week 46 (1995) and ended in
week 10 (1996). Peak incidence reached 39 per 10000
inhabitants per week. Most of the circulating viruses
were of type influenza A}H3N2}Netherlands}218}95.
There was good matching between the vaccine (with
A}Johannesburg}33}94 strains) and the predominant
influenza strain in this season, and circulating viruses
were antigenic similar to those in the preceding two
seasons (1992–3 and 1993–4). The second season
started in week 48 (1996) and ended in week 11 (1997).
Its peak incidence reached 29 per 10000 inhabitants
per week. Due to antigenic drift this season’s
predominant strain (influenza A}Netherlands}172}96
and influenza A}Netherlands}286}97) was substan-
tially different from earlier years, and a smaller type B
wave followed. These strains, however, appeared to be
well covered by that year’s vaccine.
Data collection
All data were extracted anonymously from electronic
patient records and classified by a physician (AJS). At
the inclusion date general demographic characteristics
such as sex, year of birth, region and health insurance
were registered. The following prognostic indicators
were determined in the 12 months prior to vaccination
for every season: number of physician contacts,
number of contacts associated with lower airway
complaints, number of referrals (paediatrician, pul-
monologist or ear, nose and throat-physician), anti-
biotic prescriptions, use of bronchodilators, antihista-
mines, cromoglicates, inhalation and oral corticos-
teroids and atopy. Each year vaccination status was
assessed by search in free text and}or ICPC-code
R44.1.
Outcome measures
Our combined outcome measure was the occurrence
of one ormore episodes of acute lower respiratory tract
disease defined as physician-diagnosed influenza-like
illness, pneumonia, bronchitis, bronchiolitis, asthma
exacerbation or acute otitis media during the influenza
seasons. All episodes were confirmed in free text
and}or by ICPC-codes (R02-R05, R25, R29, R78,
R80, R81, R83, R91, R96, R99, or H71). Except for
acute otitis media episodes, other upper respiratory
tract infections were not included in our primary
outcome measure. Only lower respiratory tract infec-
tions and acute otitis media have traditionally been
shown to be associated with influenza and are most
likely to be reduced by vaccination.
Statistical analysis
With EPI-Info, version 6 (CDC, Atlanta, GA, USA)
we estimated that a minimal cohort size of 330
children would give us an 80% chance of detecting a
reduction of at least 50% [15, 27, 28] in outcome
events among recipients of the vaccine. We assumed
for this calculation an immunization rate of 45%, an
event rate of 25% in unvaccinated persons and a two-
sided alfa level of 5%. Statistical analysis was per-
formed using SPSS for Windows, version 8.0 (SPSS
Inc., Chicago, IL, USA). We dichotomized age into
less than 6 and 6 years or older. This cut-off was chosen
because of differences in clinical diagnosis of asthma
and hypothesized differences in risk for complications
of influenza between age groups. All analyses were
performed for the two influenza seasons separately and
for both seasons combined.
Uni- and multivariable logistic regression modelling
was used to obtain crude and adjusted odds ratios
and their 95% confidence intervals (CI) of vaccine
effectiveness. In the first stage of constructing the
multivariate model we defined vaccination status as
the exposure term and acute respiratory disease as the
dependent variable. We then added each potentially
confounding variable independently to the model to
assess its effect on the estimated vaccine effectiveness.
In the final model we only included those variables
that materially altered the effect estimate of influenza
vaccine exposure. This model was used to obtain
adjusted odds ratios in the complete cohort as well as
in subgroups. Effect modification by age category and
season was statistically tested by adding this variable
and its first-order interaction term to the final model.
We used the adjusted odds ratios as an approximation
of the relative risk and calculated the adjusted
effectiveness as follows: (1fiadjusted odds ratio)
‹100%. We used mixed effects regression modelling
with MIXOR, version 2 (D Hedeker, RD Gibbons,
IL, Chicago, USA) to take into account a possible
child effect in the pooled analysis [29]. Point estimates
and standard errors did not change substantially
compared with the conventional logistic regression
modelling.
RESULTS
Vaccination rates increased from 41% in the first
season to 45% in the second (Table 1). Vaccinees were
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Table 1. Seasonal baseline characteristics*
Characteristic
1995}6 season (nfl 349) 1996}7 season (nfl 335) Both seasons (nfl 684)
Vaccinated
(nfl 144)
Not vaccinated
(nfl 205)
Vaccinated
(nfl 149)
Not vaccinated
(nfl 186)
Vaccinated
(nfl 293)
Not vaccinated
(nfl 391)
Male sex 55 66 54 69 55 67
Age (years) mean (s.d.) 6–6 (3–1) 6–0 (3–3) 7–7 (3–1) 7–0 (3–2) 7–1 (3–1) 6–5 (3–3)
Number of GP visits,
mean (s.d.)
7–1 (5–9) 6–1 (4–9) 6–5 (5–0) 4–2 (4–2) 6–8 (5–4) 5–2 (4–6)
Number of specialist
visits, mean (s.d.)
0–3 (0–7) 0–2 (0–4) 0–3 (0–6) 0–1 (0–5) 0–3 (0–6) 0–2 (0–5)
Pulmonary medication use 84 76 77 56 80 67
Oral prednisone use 5 1 3 3 4 2
* Data are presented as percentages except where noted otherwise.
Table 2. Attack rates of acute respiratory disease, crude and adjusted effectieness by season and age category
Attack rate in
non-vaccinees
No. (%)
Attack rate in
vaccinees
No. (%)
Crude effectiveness
% (95% CI)
Adjusted effectiveness*
% (95% CI) P-value
Both seasons
All children 102 (26–1) 63 (21–5) 22 (fi11, 46) 27 (fi7, 51) 0–11
0 to 5 years 68 (43–3) 28 (28–6) 48 (10, 70) 55 (20, 75) 0–01
Not vaccinated: 157
Vaccinated: 98
6 to 13 years 34 (14–5) 35 (17–9) fi29 (fi115, 23) fi5 (fi81, 39) 0–85
Not vaccinated: 234
Vaccinated: 195
1995}6 season
All children 57 (27–8) 40 (27–8) 0 (fi61, 38) fi1 (fi68, 39) 0–97
0 to 5 years 41 (43–6) 21 (36–2) 27 (fi44, 63) 32 (fi39, 67) 0–29
Not vaccinated: 94
Vaccinated: 58
6 to 13 years 16 (14–4) 19 (22–1) fi68 (fi251, 19) fi52 (fi225, 29) 0–28
Not vaccinated: 111
Vaccinated: 86
1996}7 season
All children 45 (24–2) 23 (15–4) 43 (0, 77) 56 (18, 76) 0–01
0 to 5 years 27 (42–9) 7 (17–5) 72 (26, 89) 77 (35, 92) 0–01
Not vaccinated: 63
Vaccinated: 40
6 to 13 years 18 (14–6) 16 (14–7) 0 (fi108, 52) 31 (fi54, 69) 0–37
Not vaccinated: 123
Vaccinated: 109
* Adjusted effectivenessfl (1fiadjusted OR)‹100%.
more likely to be girls, older, have a higher medical
consumption (in primary as well as in secondary care)
and use more pulmonary medication (any of four
types) and prednisone than non-vaccinees. The mean
age of the subgroup of children under 6 years was 3–2
(standard deviation [SD] 1–4) in season one and 3–5
(SD 1–1) years in season two. Corresponding figures
for the older children were 8–6 (SD 1–9) and 9–0 (SD
1–9) years. Attack rates of acute respiratory disease in
non-vaccinees, were 28% in the 1995–6 and 24% in
the 1996–7 season, respectively, and 26% overall
(Table 2). Acute respiratory disease was much more
common among unvaccinated children under 6 years
(43%) than among those 6 years or older (15%).
In multivariate modelling the child’s age, number
of physician contacts, number of referrals, use of
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pulmonary medication and use of oral prednisone in
the year preceding baseline confounded the associ-
ation between vaccination status and the outcome and
were therefore included in the final model. Although
the point estimates of vaccine effectiveness differed
substantially among the two seasons, differences were
not statistically significant (P" 0–10). Overall, the
influenza vaccination was associated with a 27%
reduction in the occurrence of acute respiratory
disease (95% CIfi7 to 51%, Pfl 0–11, Table 2). We
recorded a statistically significant reduction of acute
respiratory disease of 56% (95% CI 18 to 76%, Pfl
0–01) in the 1996–7 season only.
Overall, a statistically significant higher protective-
ness (Pfl 0–02 for interaction) was observed in
children less than 6 years of age (55%, 95% CI 20
to 75%, Pfl 0–01) than in older children (fi5%, 95%
CI fi81 to 39%, Pfl 0–85). In children under 6 years
of age, the vaccine was associated with a 32%
reduction (95% CI fi39% to 67%) in the outcome in
the 1995–96 season and a 77% (95% CI 35 to 92%)
reduction of outcomes in the 1996–7 season.
DISCUSSION
Our study demonstrates that children with asthma
experience significant respiratory morbidity during
influenza epidemics. Almost a quarter of these
children visited the primary care physician during the
influenza epidemics. Importantly, such morbidity
occurred in 4 out of 10 infants and pre-school children
with asthma. Our data further suggest that the
conventional influenza vaccine substantially reduced
the occurrence of acute respiratory disease in this
young high-risk group during the second influenza
epidemic. Age seems therefore more important than
the certainty or severity of the asthma-diagnosis.
To appreciate these findings, some potential limita-
tions of our study need to be addressed. The size of the
cohort was large enough to demonstrate an expected
50% reduction of outcomes resulting from the vaccine
based on earlier observations. Sugaya et al. [15], for
example, recorded a 49% reduction in febrile episodes
in vaccinated asthmatic children aged 2–14 years,
Khan et al. [28] demonstrated a vaccine efficacy for
preventing school absenteeism due to respiratory
illness of 56% in healthy children and Gross et al. [27]
recorded a 50% reduction in influenza-related illness
among the elderly in a large meta-analysis. In the
1996–7 season we were therefore able to demonstrate
a statistically significant vaccine protectiveness of
56% overall and of 77% in the youngest asthmatics.
However, vaccine protectiveness seemed less in the
first season (1%). Although in that season a protec-
tiveness of 32% was observed in the younger children,
overall no protectiveness could be demonstrated
mainly due to negative results in the older group
(fi52%). We believe that the effect estimate and its
corresponding large confidence intervals in this older
subgroup could at least partly be attributed to a lack
of sufficient statistical power since the incidence of
outcomes in unvaccinated older children was much
lower than expected. Residual immunity resulting
from exposure to similar influenza strains in previous
seasons might also have led to a decreased contrast
between unvaccinated and vaccinated children.
As no statistically significant modification of effec-
tiveness across the two seasons was found and the
circulating viruses and the vaccine composition dif-
fered substantially in both seasons, we pooled the data
to enhance statistical power [30]. In vaccinated infants
and pre-school children the occurrence of acute
respiratory disease was halved (Pfl 0–01), but among
the older children no effectiveness was found (Pfl
0–85). Despite the fact that the same children were
counted twice in these pooled analysis and observa-
tions were therefore statistically dependent, results of
mixed effect regression modelling were essentially the
same.
Another explanation for finding no effect in the
older children and a potential underestimation of the
vaccine effectiveness in the younger group could have
resulted from incomparability of prognosis among
comparison groups. In general, vaccinated children
had most probably more severe asthma than unvac-
cinated children and risk of significant respiratory
disease resulting from infections is therefore higher in
vaccinated children. We have tried to adjust for this
so-called ‘confounding by indication’ by controlling
for the various available prognostic indicators in the
study design and data analysis [31]. Statistical ad-
justment led to a substantial increase in the point
estimate of the vaccine’s protectiveness in the older
group. However, confounding by unmeasured factors
might also have been responsible for detecting no
statistically significant protectiveness.
Studying clinical instead of serological outcomes
can lead to non-differential misclassification of out-
come values and consequently to an underestimation
of the vaccine’s effectiveness. This effect has been
demonstrated in a recent study by Heikkinen et al.
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who reported a 83% reduction of influenza-associated
acute otitis media by the vaccine, the reduction of
acute otitis media overall being 36% [10, 32]. Ob-
viously, the difference depends upon the influenza-
attributable fraction of outcomes. We restricted our
outcome measurements to the influenza epidemic
periods when influenza viruses are mainly circulating
and an important respiratory pathogen [2, 3, 25, 26].
The fact that the incidence rates of acute respiratory
disease were reduced by vaccination support the
contention that influenza played a major role in these
episodes. An advantage of studying clinical instead of
serological outcomes is that these data are more
relevant from a patient’s and physician’s point-of-
view.
Some might argue that prior influenza vaccination
or inadequate dosage of vaccination might have
influenced our effectiveness estimates. The informa-
tion in medical records on vaccination status in 1994
and received number of vaccine doses was, however,
incomplete and we could not collect valid data on
these issues. We have examined a potential effect
modification by prior vaccination status. Most of the
vaccinees in 1996 also received the vaccine in 1995
(83%). We could not establish a statistically signifi-
cant difference in effectiveness as compared with those
few subjects who received the vaccine for the first
time. This is in agreement with the findings of Beyer et
al. who did not observe modified vaccine effectiveness
resulting from prior immunization in a large meta-
analysis [33].
Our study is unique in that it addressed the clinical
effectiveness of influenza vaccination on the reduction
of acute respiratory disease in asthmatic children. In a
prior study by Sugaya et al. the vaccine provided a
49% reduction of influenza-related febrile illnesses in
asthmatic children aged 2–14 years [15], a figure
similar to our findings. They found, however, the
vaccine to be more effective in children older than 7
years of age, but effect modification by age was not
statistically confirmed. In 1974 Bell et al. observed a
66% reduction in hospitalization days due to influ-
enza-like-illness and to influenza-like-illness and as-
thma, but not due to asthma alone [34]. Although
both studies, like ours, included asthmatic children,
there are some major differences. Neither study
measured the effect of vaccination on acute respiratory
disease, nor were they primary care-based, multi-
season or did they adjust for potential confounders.
So far, only protection against acute otitis media has
been suggested in healthy children in three pro-
spective, single-season trials, with an effectiveness of
30–40% [8–10].
In conclusion, the conventional influenza vaccine
appears to offer protection against relevant morbidity
in asthmatic infants and pre-school children in return
for a safe and relatively cheap intervention. Expansion
of the indication range to include children with
‘probable asthma’ and ‘recurring airway diseases’
under 6 years of age needs to be seriously considered.
Larger, preferably experimental, studies are needed to
establish whether older asthmatic children benefit
from the vaccine as well.
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